RESUMO
This cross-sectional study examines spending by health care plans and enrollees on products with accelerated approval.
Assuntos
Planos de Assistência de Saúde para Empregados , Gastos em Saúde , Humanos , Custo Compartilhado de Seguro , Preparações FarmacêuticasRESUMO
This cross-sectional study examines and compares the time taken from the accelerated approval of cancer and noncancer drugs to the initiation of confirmatory studies in the US.
Assuntos
Antineoplásicos , Neoplasias , Humanos , Estados Unidos , Neoplasias/tratamento farmacológico , Antineoplásicos/uso terapêutico , Aprovação de Drogas , United States Food and Drug AdministrationRESUMO
The dataset summarized in this article includes a nationwide prevalence sample of U.S. military Veterans who were aged 65 years or older, dually enrolled in the Veterans Health Administration and traditional Medicare and had a previous diagnosis of diabetes (diabetes mellitus) as of December 2005 (N = 275,190) [1]. Our data were originally used to develop and validate prognostic indices of 5- and 10-year mortality among older Veterans with diabetes. We include various potential predictors including demographics (e.g., sex, age, marital status, and VA priority group), healthcare utilization (e.g., # of outpatient visits, # days of inpatient stays), medication history, and major comorbidities. This novel dataset provides researchers with an opportunity to study the associations between a large variety of individual-level risk factors and longevity for patients living with diabetes.
